**ABSTRACT**

**INTRODUCTION**

There has been important progress in the treatment of patients with infective endocarditis over the past several decades. New pharmacologic approaches, such as daptomycin, which has a rapid bactericidal activity, are now being tested. However, there are few data on the susceptibility of these isolates to new agents.

**RESULTS**

Daptomycin was active against 99.8% of Gram-positive strains collected from cancer patients. However, the susceptibility results for daptomycin were not consistent across the antimicrobials tested, and significant differences were observed between cancer patients and non-cancer patients.

**CONCLUSIONS**

Daptomycin was active against Gram-positive bacteria strains collected from cancer patients in the USA hospitals, but susceptibility was not only active against 99.8% of strains and showed a high level against vancomycin (87.5% susceptibility).

**SELECTED REFERENCES**